In Silico Drug Modeling

Creating an effective therapeutic does not end with the identification of a compound with high activity and specificity against a protein target. The pharmaceutical needs a delivery vehicle that safely and efficiently treats the disease within a patient. Identifying the right solid form of the drug, in terms of different polymorphs or crystal morphology can significantly decrease the time required to develop the final product formulation and avoid costly late-stage project failures.

A Comprehensive Suite

BIOVIA Materials Studio provides a comprehensive suite of methods to model the behavior of drug compounds in silico, which can help to guide development efforts, minimizing risk and supporting IP capture.

Crystallization
Stability
Solubility

Crystallization

Determine crystal structures for drug compounds via simulated powder diffraction spectra and refine them against experimental results
Explore potential polymorphs of a compound directly from its molecular structure
Predict the morphology of a crystalline material from its crystal structure and explore the effects of solvents and impurities on growth of crystal facets